DANCANN PHARMA A/S

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Estimate generation in progress, please wait...
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  29.0% 0.0% 0.0% 3.0% 9.9%  
Credit score (0-100)  3 0 0 57 24  
Credit rating  B N/A N/A BBB BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 -0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  0.0 0.0 0.0 -7,575 -5,299  
EBITDA  0.0 0.0 0.0 -15,071 -13,408  
EBIT  0.0 0.0 0.0 -16,026 -59,353  
Pre-tax profit (PTP)  0.0 0.0 0.0 -18,443.0 -62,349.0  
Net earnings  0.0 0.0 0.0 -16,064.0 -62,260.0  
Pre-tax profit without non-rec. items  0.0 0.0 0.0 -18,443 -62,349  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 9,281 3,936  
Shareholders equity total  0.0 0.0 0.0 62,793 9,506  
Interest-bearing liabilities  0.0 0.0 0.0 7,557 6,774  
Balance sheet total (assets)  0.0 0.0 0.0 73,276 17,710  

Net Debt  0.0 0.0 0.0 -2,580 5,884  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 0.0 0.0 -7,575 -5,299  
Gross profit growth  0.0% 0.0% 0.0% 0.0% 30.0%  
Employees  0 0 0 10 11  
Employee growth %  -100.0% 0.0% 0.0% 0.0% 10.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 0 0 73,276 17,710  
Balance sheet change%  -100.0% 0.0% 0.0% 0.0% -75.8%  
Added value  0.0 0.0 0.0 -16,026.0 -13,408.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -4 0 0 44,883 -87,847  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 0.0 0.0 -1.0 -2.0  

Profitability 
2019
2019/12
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 0.0% 0.0% 211.6% 1,120.1%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 0.0% 0.0% -21.1% -132.0%  
ROI %  0.0% 0.0% 0.0% -22.0% -138.6%  
ROE %  0.0% 0.0% 0.0% -25.6% -172.2%  

Solidity 
2019
2019/12
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Equity ratio %  0.0% 0.0% 0.0% 85.7% 53.7%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% 0.0% 17.1% -43.9%  
Gearing %  0.0% 0.0% 0.0% 12.0% 71.3%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 79.4% 32.3%  

Liquidity 
2019
2019/12
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Quick Ratio  0.0 0.0 0.0 1.4 0.2  
Current Ratio  0.0 0.0 0.0 1.4 0.2  
Cash and cash equivalent  0.0 0.0 0.0 10,137.0 890.0  

Capital use efficiency 
2019
2019/12
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 97.3 47.5  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 0.0 0.0 4,312.0 -6,184.0  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 -1,603 -1,219  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 -1,507 -1,219  
EBIT / employee  0 0 0 -1,603 -5,396  
Net earnings / employee  0 0 0 -1,606 -5,660